A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma

Part of paid clinical trials in Stanford, California.

Sponsor
Treeline Biosciences, Inc.
Study ID
NCT06733441
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • TLN-254 — DRUG
    TLN-254 will be administered orally at a specified dose on specified days depending on treatment allocation.
  • TLN-254 — DRUG
    TLN-254 will be administered orally at a specified dose on specified days.

Study Details

The primary purpose of this study is to evaluate the anti-tumor activity of TLN-254 monotherapy in participants with relapsed or refractory T-cell lymphoma.

Key Dates

Start date
Dec 16, 2024
Status verified
Oct 2025
Primary completion
Nov 15, 2026
Completion
Nov 15, 2028

Study Design

Enrollment
50 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Cohort 1: TLN-254 Single Agent
  • Experimental: Cohort 2: TLN-254 Single Agent

Primary Outcome Measure

Percentage of Participants With Objective Response [ Time Frame: Up to 2 years ]

Central Contacts

Locations (4)

FacilityCityStateZIPSite coordinators
Stanford Cancer InstituteStanfordCalifornia94305
Nana Shakhnazaryan
[email protected]
650-304-9443
Washington University School of MedicineSt LouisMissouri63110
Molly Dubois, Sr. Clinical Research Coordinator
[email protected]
314-273-1486
Memorial Sloan Kettering Cancer CenterNew YorkNew York10065
Catherine Maccaro
[email protected]
646-608-2883
Sarah Cannon Research InstituteNashvilleTennessee37203
AskSarah Help Line
844-482-4812

Find similar trials in Stanford, CA

By research site
Stanford Cancer Institute· Stanford, CAWashington University School of Medicine· St Louis, MOMemorial Sloan Kettering Cancer Center· New York, NYSarah Cannon Research Institute· Nashville, TN

Related Studies